Format

Send to

Choose Destination
Gynecol Oncol. 2017 Sep;146(3):531-537. doi: 10.1016/j.ygyno.2017.06.018. Epub 2017 Jun 24.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Author information

1
Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: hensleym@MSKCC.ORG.
2
The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. Electronic address: spatel@mdanderson.org.
3
Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Margaret.vonmehren@fccc.edu.
4
Stanford Hospital and Clinics, Stanford, CA, USA. Electronic address: kganjoo@stanford.edu.
5
Seattle Cancer Care Alliance/University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Electronic address: robin.jones4@nhs.net.
6
Arthur James Cancer Center, Columbus, OH, USA. Electronic address: arthurstaddon@pennoncology.com.
7
Indiana University, Simon Cancer Center, Indianapolis, IN, USA. Electronic address: drushing@iupui.edu.
8
University of Iowa Hospitals and Clinics, Iowa City, IA, USA. Electronic address: mohammed-milhem@uiowa.edu.
9
St. Joseph's Hospital & Medical Center, Phoenix, AZ, USA. Electronic address: bradley.monk@usoncology.com.
10
Janssen Research & Development LLC, Raritan, NJ, USA. Electronic address: GWang14@its.jnj.com.
11
Janssen Research & Development LLC, Raritan, NJ, USA. Electronic address: smccar15@ITS.JNJ.com.
12
Janssen Research & Development LLC, Raritan, NJ, USA. Electronic address: RKnoblau@its.jnj.com.
13
Janssen Research & Development LLC, Raritan, NJ, USA. Electronic address: TParekh1@ITS.JNJ.COM.
14
Mount Sinai School of Medicine, New York, NY, USA. Electronic address: RMaki@northwell.edu.
15
Dana-Farber Cancer Institute, Harvard Medical School, and Ludwig Center at Harvard, Boston, MA, USA. Electronic address: gdemetri@partners.org.

Abstract

OBJECTIVE:

Trabectedin demonstrated significantly improved disease control in leiomyosarcoma and liposarcoma patients in a global phase 3 trial (NCT01343277). A post hoc analysis was conducted to assess the efficacy and safety of trabectedin or dacarbazine in women with uterine leiomyosarcoma (uLMS), the largest subgroup of enrolled patients (40%).

METHODS:

Of 577 patients randomized 2:1 to receive trabectedin 1.5mg/m2 by 24-hour IV infusion or dacarbazine 1g/m2 by 20-120-minute IV infusion once every three weeks, 232 had uLMS (trabectedin: 144; dacarbazine: 88). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), objective response rate (ORR), clinical benefit rate (CBR: complete responses+partial responses+stable disease [SD] for at least 18weeks), duration of response (DOR), and safety.

RESULTS:

PFS for trabectedin was 4.0months compared with 1.5months for dacarbazine (hazard ratio [HR]=0.57; 95% CI 0.41-0.81; P=0.0012). OS was similar (trabectedin 13.4months vs. dacarbazine 12.9months, HR=0.89; 95% CI 0.65-1.24; P=0.51) between groups. ORR was 11% with trabectedin vs. 9% with dacarbazine (P=0.82). CBR for trabectedin was 31% vs. 18% with dacarbazine (P=0.05); median DOR was 6.5months for trabectedin vs. 4.1months for dacarbazine (P=0.32). Grade 3/4 treatment-emergent adverse events observed in ≥10% of patients in the trabectedin group included transient aminotransferase (aspartate/alanine) elevations, anemia, leukopenia, and thrombocytopenia.

CONCLUSIONS:

In this post hoc subset analysis of patients with uLMS who had received prior anthracycline therapy, trabectedin treatment resulted in significantly longer PFS versus dacarbazine, with an acceptable safety profile. There was no difference in OS.

KEYWORDS:

Dacarbazine; Phase 3; Trabectedin; Uterine leiomyosarcoma

PMID:
28651804
PMCID:
PMC5783302
DOI:
10.1016/j.ygyno.2017.06.018
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center